Patents

Literature

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

113 results about "Viral protease" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

Viral proteases are enzymes (endopeptidases EC 3.4.2) encoded by the genetic material (DNA or RNA) of viral pathogens. The role of these enzymes is to catalyze the cleavage of specific peptide bonds in viral polyprotein precursors or in cellular proteins. In most cases these proteolytic events are essential for the completion...

Colon targeted delivery system

InactiveUS6039975ADrageesPlasticizerMedicine

A novel delivery system for targeting drugs to the colon is herein described. The system is a tablet comprised of three parts: 1) an outer enteric coating, 2) an inner semi-permeable polymer membrane containing a plasticizer and 3) a central core comprising swelling excipients and an active ingredient. The novel dosage form described herein will release the drug consistently in the colon by a time-dependent explosion mechanism. This delivery system is particularly suitable for delivering viral protease inhibitors to the colon.

Colon targeted delivery system

Colon targeted delivery system

Colon targeted delivery system

Owner:F HOFFMANN LA ROCHE & CO AG

Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors

InactiveUS6046190ABiocideOrganic chemistryRetroviral protease inhibitorViral protease

The invention relates to sulfonamide-containing hydroxyethylamine protease inhibitor compounds, their process of making, composition and method of use for inhibiting retroviral proteases such as human immunodeficiency virus.

Owner:GD SEARLE & CO

Resistance-repellent retroviral protease inhibitors

InactiveUS20050267074A1BiocideAntiviralsRetroviral protease inhibitorViral protease

Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.

Resistance-repellent retroviral protease inhibitors

Resistance-repellent retroviral protease inhibitors

Resistance-repellent retroviral protease inhibitors

Owner:SEQUOIA PHARMACEUTICALS INC

Pyrrolidine derivatives for use in treating heaptitis c virus infection

InactiveUS20060142204A1Good biological propertiesIncrease biological penetrationAntibacterial agentsBiocideDiseaseProteinase activity

The present invention relates to novel hepatitis C virus (“HCV”) protease inhibitors or other flavivirus protease inhibitors having the general structure (I) or (II), pharmaceutical compositions containing one or more such inhibitors, methods for preparing such inhibitors, uses of these compounds to treat hepatitis C and related disorders together with their use for their activity towards NS3 serine protease, intermediary compounds for the method of preparation of said compounds and screening methods. The invention specifically discloses novel chemical compounds as inhibitors of the HCV serine protease.

Pyrrolidine derivatives for use in treating heaptitis c virus infection

Pyrrolidine derivatives for use in treating heaptitis c virus infection

Pyrrolidine derivatives for use in treating heaptitis c virus infection

Owner:GENOSCI PHARMA

Resistant-repellent retroviral protease inhibitors

InactiveUS20060293286A1BiocideHydrolasesRetroviral protease inhibitorPharmaceutical drug

Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.

Resistant-repellent retroviral protease inhibitors

Resistant-repellent retroviral protease inhibitors

Resistant-repellent retroviral protease inhibitors

Owner:SEQUOIA PHARMACEUTICALS INC

.alpha.- and .beta.-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

InactiveUS6172082B1BiocidePeptide/protein ingredientsProteinase activityRetroviral protease inhibitor

.alpha.- and .beta.-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.

Owner:GD SEARLE & CO

Modified Foot-And-Mouth Disease Virus 3C Proteases, Compositions And Methods Thereof

ActiveUS20180066235A1Poor recombinant yieldLow toxicitySsRNA viruses positive-senseViral antigen ingredientsNucleotideVirus-like particle

This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.

Modified Foot-And-Mouth Disease Virus 3C Proteases, Compositions And Methods Thereof

Modified Foot-And-Mouth Disease Virus 3C Proteases, Compositions And Methods Thereof

Modified Foot-And-Mouth Disease Virus 3C Proteases, Compositions And Methods Thereof

Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SEC OF HOMELAND SECURITY

Broad-spectrum non-covalent coronavirus protease inhibitors

ActiveUS9975885B2Organic chemistryProteinase activityViral protease

This invention pertains to materials and methods for the treatment of patients with coronavirus infection and the control of zoonotic disease outbreaks using broad-spectrum non-covalent coronavirus protease inhibitors.

Broad-spectrum non-covalent coronavirus protease inhibitors

Broad-spectrum non-covalent coronavirus protease inhibitors

Broad-spectrum non-covalent coronavirus protease inhibitors

Owner:PURDUE RES FOUND INC

Resistance-repellent retroviral protease inhibitors

InactiveUS20050209301A1Prevent slow emergenceSlow emergenceBiocideOrganic chemistryRetroviral protease inhibitorViral protease

Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.

Resistance-repellent retroviral protease inhibitors

Resistance-repellent retroviral protease inhibitors

Resistance-repellent retroviral protease inhibitors

Owner:SEQUOIA PHARMACEUTICALS INC

Α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

InactiveUS6846954B2Peptide/protein ingredientsOrganic compound preparationProteinase activityRetroviral protease inhibitor

α- and β-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.

Α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

Α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

Α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

Owner:GD SEARLE & CO

Α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

InactiveUS6924286B1BiocidePeptide/protein ingredientsProteinase activityRetroviral protease inhibitor

α- and β-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.

Α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

Α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

Α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

Owner:GD SEARLE & CO

Recombinant human serum transferrins containing peptides for inducing apoptosis in HIV-1 infected cells

InactiveUS20020146794A1Minimal effectFacilitated releaseAntibody mimetics/scaffoldsVirus peptidesInfected cellMammal

A mammalian protein, like the human serum transferrin (HST), is modified with an inserted peptide sequence flanked at both ends by cleavage sites. The peptide insert contains a motif known to induce apoptosis in cells and the cleavage sites are specific for the viral protease of HIV-1. The delivery of such recombinant transferrin into an HIV-1 infected cell results in the release of the peptide which then induces apoptosis. The peptide is inserted into surface exposed loops of the N-terminal lobe of the HST containing the RGD motif flanked by two modified p17 / p24 HIV-1 protease cleavage sites. When delivered to the infected cell the cleavage of the loop inserted sequences by the HIV-1 protease results in the release of the central RGD-containing peptide sequences. Peptides containing the RGD motif (arginine, glycine, aspartic acid) have been shown to induce cell apoptosis even in small concentrations.

Recombinant human serum transferrins containing peptides for inducing apoptosis in HIV-1 infected cells

Recombinant human serum transferrins containing peptides for inducing apoptosis in HIV-1 infected cells

Recombinant human serum transferrins containing peptides for inducing apoptosis in HIV-1 infected cells

Owner:TOMYCZ NESTOR D

Synthetic route to anti-viral agents

ActiveUS9809576B1Carbamic acid derivatives preparationOrganic compound preparationAntiviral drugViral protease

The invention provides methods of synthesizing a viral protease inhibitor in high yield, without using expensive catalysts or challenging reaction conditions.

Synthetic route to anti-viral agents

Synthetic route to anti-viral agents

Synthetic route to anti-viral agents

Owner:ABBVIE INC

Α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

InactiveUS7141609B2BiocidePeptide/protein ingredientsProteinase activityRetroviral protease inhibitor

α- and β-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.

Α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

Α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

Α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

Owner:GD SEARLE & CO

Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

InactiveUS6172082B2BiocidePeptide/protein ingredientsProteinase activityRetroviral protease inhibitor

alpha- and beta-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.

Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

Owner:GD SEARLE & CO

Α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

InactiveUS7115618B2BiocidePeptide/protein ingredientsProteinase activityRetroviral protease inhibitor

α- and β-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.

Α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

Α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

Α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

Owner:GD SEARLE & CO

Inhibitors of coronavirus protease and methods of use thereof

InactiveUS20050267071A1BiocideBoron compound active ingredientsViral proteaseBiochemistry

This invention provides organic boron-containing compounds, compositions thereof, and methods of using such compounds and compositions for inhibiting coronavirus protease(s) and for treating infections.

Inhibitors of coronavirus protease and methods of use thereof

Inhibitors of coronavirus protease and methods of use thereof

Inhibitors of coronavirus protease and methods of use thereof

Owner:FULCRUM PHARMA +1

Macrocyclic compounds as antiviral agents

ActiveUS8927569B2Antibacterial agentsBiocideProteinase activityViral protease

A class of macrocyclic compounds of formula (I), wherein R1, R3, R4, Ra, Rb, A, Z, Y, X, M, W, n and m are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes 5 for the synthesis and use of such macrocyclic compounds for treating or preventing HCV infection. Formula (I):

Macrocyclic compounds as antiviral agents

Macrocyclic compounds as antiviral agents

Macrocyclic compounds as antiviral agents

Owner:MERCK SHARP & DOHME LLC

Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors

InactiveUS6861539B1BiocidePeptide/protein ingredientsProteinase activityRetroviral infection

Selected bis-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.

Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors

Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors

Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors

Owner:GD SEARLE & CO

Resistance-repellent retroviral protease inhibitors

InactiveUS20060258627A1BiocideOrganic chemistryRetroviral protease inhibitorViral protease

Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.

Resistance-repellent retroviral protease inhibitors

Resistance-repellent retroviral protease inhibitors

Resistance-repellent retroviral protease inhibitors

Owner:SEQUOIA PHARMACEUTICALS INC

Resistance-repellent retroviral protease inhibitors

InactiveUS7285566B2BiocidePeptidesRetroviral protease inhibitorMedicine

Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.

Resistance-repellent retroviral protease inhibitors

Resistance-repellent retroviral protease inhibitors

Resistance-repellent retroviral protease inhibitors

Owner:SEQUOIA PHARMACEUTICALS INC

Structure and application of Enterovirus 71 3C protease

ActiveCN102199586ADiscover specificityHydrolasesMicroorganism based processesVirus ProteinRNA virus

The invention discloses a structure and application of an Enterovirus 71 (EV71) 3C protease and belongs to the field of RNA virus protein. The invention also discloses an application of the 3C protease and a substrate binding groove thereof in drug design. The protein provided by the invention has a special substrate binding groove and new EV71 virus 3C protease drugs are designed according to the spatial structure of the substrate binding groove, thus the inhibitors aiming at the EV71 virus 3C protease, which are more specific and have better effect, can be obtained, potential drug candidates can be provided for the clinical treatment of hand, foot and mouth disease and the EV71 virus 3C protease has very high application value.

Structure and application of Enterovirus 71 3C protease

Structure and application of Enterovirus 71 3C protease

Structure and application of Enterovirus 71 3C protease

Owner:INST OF MICROBIOLOGY - CHINESE ACAD OF SCI

Difluoroalkylcyclopropyl amino acids and esters, and syntheses thereof

ActiveUS9809534B1Carbamic acid derivatives preparationOrganic compound preparationViral proteaseAmino acid

The invention provides methods of synthesizing compounds in an asymmetric or enantioenriched fashion, wherein the compounds are useful intermediates in the synthesis of viral protease inhibitors.

Difluoroalkylcyclopropyl amino acids and esters, and syntheses thereof

Difluoroalkylcyclopropyl amino acids and esters, and syntheses thereof

Difluoroalkylcyclopropyl amino acids and esters, and syntheses thereof

Owner:ABBVIE INC

3D-Structure model of SARS coronavirus 3CL protease and anti-SARS drugs

InactiveUS20060142383A1BiocideHydrolasesCinanserinProteinase activity

The present invention discloses 3D-structure of SARS-CoV Viral 3CL Protease obtained through molecular simulation. The 3D-structure is used as a drug target for screening the existing medical database CMC (Comprehensive Medicinal Chemistry, MDL Information System, Inc.), and a group of compounds which have the activity of inhibiting SARS-CoV virus 3CL Protease are found. Cinanserin was tested at molecular and viral levels, and it was found to be able to inhibit the SARS-CoV viral 3CL protease and SARS-CoV viruses. Cinanserin analogs were synthesized and tested at molecular and viral levels, they were found to be able to inhibit the SARS-CoV virus 3CL Protease and SARS-CoV viruses, and may be used for treating and / or preventing SARS-CoV virus infection.

3D-Structure model of SARS coronavirus 3CL protease and anti-SARS drugs

3D-Structure model of SARS coronavirus 3CL protease and anti-SARS drugs

3D-Structure model of SARS coronavirus 3CL protease and anti-SARS drugs

Owner:SHANGHAI LEAD DISCOVERY PHARMA +1

HIV-1 virus protease inhibitor drug resistance mutation detection kit and method

InactiveCN103215348AHigh degree of integrationHigh sensitivityMicrobiological testing/measurementDNA/RNA fragmentationGenes mutationMutation detection

The invention relates to an HIV-1 protease inhibitor drug resistance mutation detection method and a kit. Specifically, the invention also discloses a probe for detection of human immunodeficiency virus protease gene drug resistance mutation, and the probe includes a probe for detection of protease gene D30N mutation, a probe for detection of protease gene V32I mutation, a probe for detection of protease gene M46I and M46L mutation, a probe for detection of protease gene I47V and I47A mutation, a probe for detection of protease gene G48V mutation, a probe for detection of protease gene I50V mutation, a probe for detection of protease gene I54V mutation, a probe for detection of protease gene V82A, V82F, V82T and V82S mutation, a probe for detection of protease gene I84V mutation, a probe for detection of protease gene N88D mutation, and a probe for detection of protease gene L90M mutation.

HIV-1 virus protease inhibitor drug resistance mutation detection kit and method

HIV-1 virus protease inhibitor drug resistance mutation detection kit and method

HIV-1 virus protease inhibitor drug resistance mutation detection kit and method

Owner:ZHEJIANG UNIV

Drug screening model of targeting coronavirus protease and application thereof

ActiveCN102021145AAvoid the risk of infectionImprove throughputMicrobiological testing/measurementMicroorganism based processesDNA constructReticulum cell

The present invention provides a novel cell-based drug screening model of targeting coronavirus protease. In the processing products of the coronavirus polyprotein 1a(1ab), nsp3, nsp4 and nsp6 contain transmembrane (TM) domains which can mediate the protein to locate on the cell endoplasmic reticulum (ER) membrane. Using the characteristics that nsp3, nsp4 and nsp6 contain transmembrane domains and the protein is located in the cell, the present invention constructs a eukaryotic expression DNA construct by secretion reporter gene, wherein the eukaryotic expression DNA construct consists of coronavirus proteases - protease recognition sites - secretion reporter genes. After cell transfection, the expression products of the active releasing reporter gene are cut by the coronavirus protease and are secreted into the cellular supernatant; the activity of the coronavirus protease is detected by the activity of the reporter genes in the cellular supernatant and is used for coronavirus drug screening.

Drug screening model of targeting coronavirus protease and application thereof

Drug screening model of targeting coronavirus protease and application thereof

Drug screening model of targeting coronavirus protease and application thereof

Owner:INST OF RADIATION MEDICINE ACAD OF MILITARY MEDICAL SCI OF THE PLA

Activatable toxin complexes comprising a cleavable inhibitory peptide

InactiveUS20130202598A1Avoid multiplicationAvoid spreadingAntibacterial agentsAntimycoticsDiseaseViral protease

The present invention relates to activatable toxin complexes which include a cleavable inhibitory peptide. More specifically, the complexes comprise a cell targeting domain, a toxin catalytic domain, a specific protease cleavage site and an inhibitory peptide domain. The inhibitory peptide prevents the catalytic domain from exerting toxic effects until its release from the complex by the action of a protease, such a viral protease, at the protease cleavage site. Further provided are pharmaceutical compositions comprising the complexes and use thereof for treating infections and malignant disease.

Activatable toxin complexes comprising a cleavable inhibitory peptide

Activatable toxin complexes comprising a cleavable inhibitory peptide

Activatable toxin complexes comprising a cleavable inhibitory peptide

Owner:RAMOT AT TEL AVIV UNIV LTD

Broad-spectrum non-covalent coronavirus protease inhibitors

ActiveUS20170313685A1Organic chemistryProteinase activityViral protease

This invention pertains to materials and methods for the treatment of patients with coronavirus infection and the control of zoonotic disease outbreaks using broad-spectrum non-covalent coronavirus protease inhibitors.

Broad-spectrum non-covalent coronavirus protease inhibitors

Broad-spectrum non-covalent coronavirus protease inhibitors

Broad-spectrum non-covalent coronavirus protease inhibitors

Owner:PURDUE RES FOUND INC

Application of MERS-CoV 3CLpro (Middle East respiratory syndrome coronavirus 3C-like protease) as deubiquitinating enzyme and interferon inhibitor

InactiveCN110257357AExpand new knowledgeCompound screeningApoptosis detectionHuman coronavirusProteinase activity

The invention relates to the field of biomedicine, in particular to application of MERS-CoV 3CLpro (Middle East respiratory syndrome coronavirus 3C-like protease) as a deubiquitinating enzyme and interferon inhibitor. The invention provides a novel deubiquitinating enzyme and interferon inhibitor; the new understanding of the functionality of human coronavirus proteinase can be expanded; theoretical basis can be provided for the research on coronavirus and host antiviral natural immunization and the research on antiviral drugs using viral proteinase as a target.

Application of MERS-CoV 3CLpro (Middle East respiratory syndrome coronavirus 3C-like protease) as deubiquitinating enzyme and interferon inhibitor

Application of MERS-CoV 3CLpro (Middle East respiratory syndrome coronavirus 3C-like protease) as deubiquitinating enzyme and interferon inhibitor

Application of MERS-CoV 3CLpro (Middle East respiratory syndrome coronavirus 3C-like protease) as deubiquitinating enzyme and interferon inhibitor

Owner:ACADEMY OF MILITARY MEDICAL SCI

Substituted quinoline-2-formaldehyde-phenylhydrazone derivative, and preparation method and application thereof

InactiveCN102731394AInhibition of replicationBlock life cycleOrganic chemistryAntiviralsQuinolineEnzyme inhibitor

The present invention relates to a substituted-quinoline-2-formaldehyde-phenylhydrazone derivative and a preparation method and application thereof, and in particular relates to a novel 4-acyl-quinoline-2-formaldehyde-phenylhydrazone derivative, and a preparation method and application thereof to preparation of therapeutic drugs for dengue fever and dengue hemorrhagic fever caused by dengue virus. A structure of the compound is shown as a formula 1. The compound can be used as a protease inhibitor for a dengue virus NS2B-NS3, so as to block further proliferation of the dengue virus in a host.

Substituted quinoline-2-formaldehyde-phenylhydrazone derivative, and preparation method and application thereof

Substituted quinoline-2-formaldehyde-phenylhydrazone derivative, and preparation method and application thereof

Substituted quinoline-2-formaldehyde-phenylhydrazone derivative, and preparation method and application thereof

Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI +1

Popular searches

BULK ACTIVE INGREDIENT Active ingredient Excipient Enteric coating Delivery system Polymer Pharmaceutical preservatives Coating drugs Target drug Virus inhibitors

Who we serve

R&D Engineer
R&D Manager
IP Professional

Why Patsnap Eureka

Industry Leading Data Capabilities
Powerful AI technology
Patent DNA Extraction

Social media

Patsnap Eureka Blog

PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com